Burning Rock Biotech

Burning Rock Biotech Ltd. engages in the investment of medical fields. It specializes in next-generation sequencing diagnostics solutions for precision medicine in oncology. The firm operates through the following segments: Central Laboratory Business, In-Hospital Business and Pharma Research and Development Services. Its products and clinical applications include companion diagnostics for targeted therapy and immunotherapy, benign, malignant tumor diagnosis, minimal residual disease monitoring, tumor recurrence and progression prediction and tumor susceptibility tests. The company was founded by Yu Sheng Han in January 2014 and is headquartered in Guangzhou, China.

Earnings data Q4 2020

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Burning Rock Biotech achieves Q1 profitability, shifts focus to in-hospital services

Burning Rock Biotech's Q1 2024 performance marked by profitability, improved efficiency, and strategic revenue transition. Challenges overcome with a focus on sustained profitability and positive breakeven targets.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

GUANGZHOU, China, Aug. 04, 2022 (GLOBE NEWSWIRE) -- Burning Rock Biotech Limited (NASDAQ: BNR, the “Company” or “Burning Rock”), a company focused on the application of next generation sequencing (NGS) technology in the field of precision oncology, today announced that it plans to release its unaudited financial results for the second quarter of 2022 before the U.S. market opens on August 31, 2022. Following the release, company management will host a conference call at 8:30 a.m. ET (8:30 p.m. Hong Kong time) on the same day to discuss its financial results for the second quarter of 2022.

Burning Rock Provides Second Quarter 2022 Business Updates and Schedules Earnings Release on August 31, 2022

GUANGZHOU, China, Aug. 03, 2022 (GLOBE NEWSWIRE) -- Burning Rock Biotech Limited (NASDAQ: BNR, the “Company” or “Burning Rock”), a company focusing on the application of next generation sequencing (NGS) technology in the field of precision oncology, today announced that it will hold its annual general meeting (“AGM”) on September 8, 2022 at 10:00 a.m. (local time) at the Company's Shanghai office at 5/F, Building 1, No. 138 Xinjunhuan Road, Minhang District, Shanghai.

Burning Rock Announces 2022 Annual General Meeting to be Held on September 8, 2022

GUANGZHOU, China, July 14, 2022 (GLOBE NEWSWIRE) -- Burning Rock Biotech Limited (NASDAQ: BNR, the “Company” or “Burning Rock”), a company focused on the application of next generation sequencing (NGS) technology in the field of precision oncology, today announced the resignation of Ms. Yunxia Yang as a director from the board of directors of the Company (the “Board”) and a member of the compensation committee of the Board. Mr. Feng Deng, an existing director of the Board, has been appointed as a new member to the compensation committee to fill the vacancy created by Ms. Yang's resignation.

Burning Rock Announces Resignation of Director

CHENGDU, China, June 30, 2022 (GLOBE NEWSWIRE) -- Burning Rock Biotech Limited (NASDAQ: BNR, the “Company” or “Burning Rock”), a company focused on the application of next generation sequencing (NGS) technology in the field of precision oncology, today announced the launch of the PREVENT (a Prospective multi-canceR Early-detection and interVENTional) study, China's first prospective interventional study to evaluate the performance of Burning Rock's early cancer detection test, OverC™, in the asymptomatic population. The study is expected to enroll 12,500 asymptomatic individuals, to evaluate the performance of the OverC™ test in detecting 6 cancers (lung, liver, colorectal, esophageal, pancreatic and ovarian cancers). These 6 cancer types cover approximately 50% of China's total cancer incidence, and 62% of cancer mortality1.

Burning Rock Announces the Launch of China's First Prospective Interventional Validation Study on Multi-Cancer Early Detection - the PREVENT Study

GUANGZHOU, China, June 24, 2022 (GLOBE NEWSWIRE) -- Burning Rock Biotech Limited (NASDAQ: BNR, the “Company” or “Burning Rock”), a company focused on the application of next generation sequencing (NGS) technology in the field of precision oncology, today announced the resignation of Mr. Jing Rong as a director from the Board, and the appointment of Dr. Licen Lisa Xu as an independent director to the Board.

Burning Rock Announces Changes to Board Composition

GUANGZHOU, China, June 21, 2022 (GLOBE NEWSWIRE) -- Burning Rock Biotech Limited (NASDAQ: BNR, the “Company” or “Burning Rock”), a company focused on the application of next generation sequencing (NGS) technology in the field of precision oncology, today announced that its board of directors has authorized a share repurchase plan under which the Company may repurchase its Class A ordinary shares in the form of American depositary shares (“ADSs”) with an aggregate value of up to US$10 million during a 12-month period (the “Share Repurchase Program”).

Burning Rock Announces US$10 Million Share Repurchase Program

GUANGZHOU, China, June 21, 2022 (GLOBE NEWSWIRE) -- Burning Rock Biotech Limited (NASDAQ: BNR, the “Company” or “Burning Rock”), a company focused on the application of next generation sequencing (NGS) technology in the field of precision oncology, today announced that the Board of Directors of the Company (the “Board”) approved a motion to pursue an alternative listing of the Company's Class A ordinary shares on an internationally recognized stock exchange. The alternative listing is expected to offer fungibility with the company's American depositary shares (“ADSs”) that are currently listed on Nasdaq, in order to ensure continued and seamless trading for shareholders amid an evolving market and regulatory environment. The Board also authorized the Company's senior management to engage relevant professional parties, proceed with the relevant preparatory work and undertake the necessary procedures with respect to the alternative listing.

Burning Rock Announces Plan to Pursue An Alternative Listing

SHANGHAI , June 15, 2022 /PRNewswire/ -- Burning Rock (NASDAQ:BNR) presented the final results from the multi-center case-control THUNDER study (THe UNintrusive Detection of EaRly-stage cancer, NCT04820868) in a poster entitled "Unintrusive multi-cancer detection by circulating cell-free DNA methylation sequencing (THUNDER): development and independent validation studies" at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting. This is a comprehensive review of clinical performance after the four-year THUNDER study.

Burning Rock Presents Latest Clinical Data from THUNDER Study at 2022 ASCO Annual Meeting

ARK Genomic Revolution Multi-Sector ETF

Editas Medicine

Ionis Pharma

Cathie Wood has recently sold off large positions in several gene-editing stocks from her ARKG ETF. What's behind Wood's latest moves?

Cathie Wood Is Selling Gene Editing Stocks. Here's Why.

SHANGHAI , June 1, 2022 /PRNewswire/ -- Burning Rock Biotech Limited (NASDAQ: BNR, the "Company" or "Burning Rock") announced that it has received CE marking for its OverC™ Multi-Cancer Detection Blood Test manufactured in both the US and China facilities (Identification Number: DE/CA20/01-IVD-Luxuslebenswelt-523/22, DE/CA20/01-IVD-Luxuslebenswelt-524/22). OverC™ Multi-Cancer Detection Blood Test is a qualitative next-generation sequencing (NGS)-based in vitro diagnostic device for the detection of DNA methylation markers using cfDNA isolated from human peripheral whole blood.

Burning Rock Receives CE Mark for its OverC™ Multi-Cancer Detection Blood Test Kit

Burning Rock Biotech Limited (NASDAQ:BNR ) Q1 2022 Earnings Conference Call May 31, 2022 8:30 AM ET Company Participants Yusheng Han - Founder, Chairman & CEO Leo Li - CFO Shannon Chuai - COO Conference Call Participants Max Masucci - Cowen & Company Alexis Yan - Morgan Stanley Operator Good day, ladies and gentlemen, thank you for standing by, and welcome to Burning Rock 2022 First Quarter Earnings Conference Call. This presentation contains forward-looking statements.

Burning Rock Biotech Limited (BNR) CEO Yusheng Han on Q1 2022 Results - Earnings Call Transcript

GUANGZHOU, China, May 31, 2022 (GLOBE NEWSWIRE) -- Burning Rock Biotech Limited (NASDAQ: BNR, the “Company” or “Burning Rock”), a company focused on the application of next generation sequencing (NGS) technology in the field of precision oncology, today reported financial results for the three months ended March 31, 2022.

Burning Rock Reports First Quarter 2022 Financial Results

GUANGZHOU, China, May 16, 2022 (GLOBE NEWSWIRE) -- Burning Rock Biotech Limited (NASDAQ: BNR, the “Company” or “Burning Rock”), a company focused on the application of next generation sequencing (NGS) technology in the field of precision oncology, today announced that it plans to release its unaudited financial results for the first quarter of 2022 before the U.S. market opens on May 31, 2022. Following the release, company management will host a conference call at 8:30 a.m. ET (8:30 p.m. Hong Kong time) on the same day to discuss its financial results for the first quarter of 2022.

Burning Rock Schedules First Quarter of 2022 Earnings Release on May 31, 2022

Adaptive Biotechnologies

The CEO of Ark Invest hasn't given up on these risky biotech stocks.

Cathie Wood Can't Get Enough of These 2 Biotech Stocks

Tesla Inc (NASDAQ: TSLA) bull Cathie Wood led Ark Investment Management on Thursday further raised its exposure in China-based biotech company Burning Rock Biotech Ltd (NASDAQ: BNR). The investment firm bought 112,150 shares — estimated to be worth $1.08 million — in the biotech company.

Tesla Bull Cathie Wood Bought $1M Shares In This Biotech Stock Today

Burning Rock Biotech Limited (BNR) CEO Yusheng Han on Q4 2021 Results - Earnings Call Transcript

GUANGZHOU, China, March 21, 2022 (GLOBE NEWSWIRE) -- Burning Rock Biotech Limited (NASDAQ: BNR, the “Company” or “Burning Rock”), a company focused on the application of next generation sequencing (NGS) technology in the field of precision oncology, today reported financial results for the three months and the year ended December 31, 2021.

Burning Rock Reports Fourth Quarter and Full Year 2021 Financial Results

GUANGZHOU, China, March 15, 2022 (GLOBE NEWSWIRE) -- Burning Rock Biotech Limited (NASDAQ: BNR, the “Company” or “Burning Rock”) today announced that the National Medical Products Administration (NMPA) approved Burning Rock's Human Nine-Gene Mutation Joint Detection Kit (reversible termination sequencing) (LungCure™ CDx) as a class III medical device. This approval demonstrates Burning Rock's industry-leading capability of working with the NMPA on bringing an innovative next generation sequencing (NGS)-based diagnostic product to the China market.

Burning Rock Secures Second NGS Kit Approval from the NMPA

GUANGZHOU, China, March 15, 2022 (GLOBE NEWSWIRE) -- Burning Rock Biotech Limited (NASDAQ: BNR, the “Company” or “Burning Rock”) today announced that it will present MRD (molecular residual disease) clinical data on non-small cell lung cancer (NSCLC) and colorectal cancer (CRC) at the following two sessions of American Association for Cancer Research (AACR) Annual Meeting on April 8, 2022:

Burning Rock to Release MRD Clinical Data on NSCLC and CRC at the Upcoming American Association for Cancer Research Annual Meeting

GUANGZHOU, China, Feb. 22, 2022 (GLOBE NEWSWIRE) -- Burning Rock Biotech Limited (NASDAQ: BNR, the “Company” or “Burning Rock”), a company focused on the application of next generation sequencing (NGS) technology in the field of precision oncology, today announced that it plans to release its unaudited financial results for the fourth quarter and full year 2021 before the U.S. market opens on March 22, 2022. Following the release, company management will host a conference call at 8:00 a.m. ET (8:00 p.m. Hong Kong time) on the same day to discuss its financial results for the fourth quarter and full year 2021.

Burning Rock Schedules Fourth Quarter and Full Year 2021 Earnings Release on March 22, 2022

GUANGZHOU, China, Dec. 28, 2021 (GLOBE NEWSWIRE) -- Burning Rock Biotech Limited (NASDAQ: BNR, the “Company” or “Burning Rock”) today announced that, based on the latest operating trends, the Company expects its 2021 revenue to be at or slightly above RMB500 million.

Burning Rock Reaffirms 2021 Revenue Guidance of RMB500 Million

GUANGZHOU, China, Dec. 27, 2021 (GLOBE NEWSWIRE) -- Burning Rock Biotech Limited (NASDAQ: BNR, the “Company” or “Burning Rock”), a company focused on the application of next generation sequencing (NGS) technology in the field of precision oncology, today announced that all shareholder resolutions proposed at the Company's 2021 annual general meeting held today were duly passed. Specifically, the shareholders passed the following resolutions approving:

Burning Rock Announces Results of 2021 Annual General Meeting

Key Takeaways: Burning Rock expects fourth-quarter revenue to grow just 6% year-on-year due to latest Covid-related travel restrictions in China

Following Rough Year, Is Burning Rock Set To Turn The Corner?

GUANGZHOU, China, Nov. 17, 2021 (GLOBE NEWSWIRE) -- Burning Rock Biotech Limited (NASDAQ: BNR, the “Company” or “Burning Rock”) today announced a strategic partnership with Merck KGaA, Darmstadt, Germany, in companion diagnostics (CDx) development for the MET inhibitor tepotinib in the mainland China market. The CDx test is based on Burning Rock's self-developed next generation sequencing (NGS)-based liquid biopsy solution, OncoCompass Target™ panel.

Merck KGaA, Darmstadt, Germany and Burning Rock Collaborate on Liquid-biopsy Based CDx Development Using Burning Rock's OncoCompass Target™

The ARK Genomic Revolution ETF ARKG, +2.01% started a position in Burning Rock Biotech BNR, +10.69% , a Chinese cancer sequencing technology company that jumped 11% after reporting third-quarter results. The loss-making biotech saw its revenue edge up 2% in the third quarter and is planning two products for early-stage cancer patients next year.

News for Burning Rock Biotech Stock (BNR)